← Back to Search

RNAi

RXI-109 for Hypertrophic Scar

Phase 2
Waitlist Available
Research Sponsored by RXi Pharmaceuticals, Corp.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 9 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing RXI-109, a treatment to reduce thick, raised scars after surgery. It targets patients who have had surgery to improve an existing scar. The treatment works by preventing the body from making too much scar tissue.

Eligible Conditions
  • Hypertrophic Scar

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~9 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 9 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Reducing the recurrence of hypertrophic scar after scar revision surgery
Secondary study objectives
Safety evaluation of RXI-109

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: RXI-109Experimental Treatment1 Intervention
RXI-109 dosed at the site of the revised hypertrophic scar
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
RXI-109
2012
Completed Phase 2
~80

Find a Location

Who is running the clinical trial?

RXi Pharmaceuticals, Corp.Lead Sponsor
6 Previous Clinical Trials
163 Total Patients Enrolled
Pamela Pavco, PhDStudy DirectorRXi Pharmaceuticals
3 Previous Clinical Trials
124 Total Patients Enrolled
~4 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top